Mortality after multivessel revascularisation involving the proximal left anterior descending artery

Masafumi Ono, Hironori Hara, Chao Gao, Hideyuki Kawashima, Rutaowang, Neil O’Leary, Joanna J Wykrzykowska, Jan J Piek, Michael J Mack, David Holmes, Marie-Claude Morice, Stuart Head, Arie Pieter Kappetein, Thilo Noack, Piroze M Davierwala, Friedrich W Mohr, Scot Garg, Yoshinobu Onuma, Patrick W Serruys

ABSTRACT

Objective We sought to investigate whether long-term clinical outcomes differ following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with three-vessel disease (3VD) and lesions in the proximal left anterior descending artery (P-LAD).

Methods This post-hoc analysis of the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) Extended Survival study included patients with 3VD who were classified according to the presence or absence of lesions located in the P-LAD. Ten-year all-cause death and 5-year major adverse cardiac or cerebrovascular events (MACCE) were assessed.

Results Among 1088 patients with 3VD, 559 (51.4%) had involvement of P-LAD and their 10-year mortality was numerically higher following PCI versus CABG (28.9% vs 21.9%; HR: 1.39, 95% CI 1.00 to 1.90). Although patients without P-LAD lesions had significantly higher 10-year mortality following PCI compared with CABG, there was no evidence of a treatment-by-subgroup interaction (28.8% vs 20.2%; HR: 1.47, 95% CI 1.03 to 2.09, pinteraction=0.837). The incidence of MACCE at 5 years was significantly higher with PCI than CABG, irrespective of involvement of P-LAD (with P-LAD: HR: 1.86, 95% CI 1.36 to 2.55; without P-LAD: HR: 1.54, 95% CI 1.11 to 2.12; pinteraction=0.408). Individualised assessment using the SYNTAX Score II 2020 established that a quarter of patients with P-LAD lesions had significantly higher mortality with PCI than CABG, whereas in the remaining three-quarters CABG had similar mortality.

Conclusions Among patients with 3VD, the presence or absence of a P-LAD lesion was not associated with any treatment effect on long-term outcomes following PCI or CABG.

Trial registration number SYNTAXES: NCT03417050; SYNTAX: NCT00114972.

INTRODUCTION

Coronary artery disease (CAD) involving the proximal left anterior descending artery (P-LAD) is considered a high-risk lesion for adverse outcomes in light of the large area of the myocardium subtended by this vessel. Consequently, revascularisation of these patients with concomitant one-vessel or two-vessel CAD has a class I recommendation for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in the current European Society of Cardiology (ESC) guidelines. Recent studies suggest a similar risk of mortality with PCI or CABG in patients with isolated P-LAD lesions; however, there is an absence of data regarding the optimal mode of revascularisation to improve very long-term prognosis in patients with a P-LAD lesion and multivessel disease (MVD). Cavalcante et al reported a numerically lower rate...
of mortality with CABG (7.0%) compared with PCI (10.1%) at 5-year follow-up (p=0.06). Given the potential superior long-term patency of a left internal mammary artery (LIMA) graft on the left anterior descending artery (LAD) compared with stenting, it is of genuine interest whether the presence of a P-LAD lesion can amplify the beneficial effects of CABG over PCI during long-term follow-up beyond 5 years.

The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial compared PCI with CABG in patients with left main CAD (LMCAD) and/or three-vessel disease (3VD). The aim of this subgroup analysis of the SYNTAX Extended Survival (SYNTAXES) study was to investigate the impact of a P-LAD lesion on long-term clinical outcomes among patients with 3VD and to compare PCI with CABG in patients with 3VD with or without a P-LAD lesion.

METHODS
Study design and patient population
The present study is a post-hoc subgroup analysis of the SYNTAXES study (NCT03417050), which was an investigator-driven, extended, 10-year follow-up of the randomised SYNTAX trial (NCT00114972) beyond its original follow-up of 5 years. In brief, the SYNTAX trial was a multicentre, randomised controlled trial performed in 85 hospitals across 18 North American and European countries which adopted an ‘all-comers’ design involving consecutive enrolment of all eligible patients with 3VD or LMCAD, except for those presenting with a myocardial infarction (MI). A total of 1800 patients with de novo 3VD and/or LMCAD who were deemed eligible for both PCI and CABG based on clinical judgement and consensus of a heart team were enrolled and randomised in a 1:1 fashion to PCI and CABG (PCI-eligible patients) or CABG (PCI-ineligible patients) registry. All patients provided written informed consent prior to participation in the SYNTAX trial.

P-LAD subgroup
In this study, patients with LMCAD were excluded to focus on the prognostic impact of P-LAD lesions independent of LMCAD. Patients were classified in the P-LAD group if they had at least one lesion of ≥50% diameter stenosis in the P-LAD, which was anatomically defined as the segment between the branching point of the left main stem and the first major septal branch, and represents segment 6 of the American Heart Association classification and the anatomical SYNTAX score.

Study endpoint
The primary endpoint of this study was all-cause death at 10 years. Vital status was confirmed by electronic healthcare record review and using national death registries. Patients with missing vital status were included in the analysis and censored at the time of ‘lost to follow-up’ or at 5 years when the recruiting centres did not participate in the SYNTAXES study for 10-year extended follow-up (a total of five patients in two centres).

We also assessed major adverse cardiac or cerebrovascular events (MACCE; defined as the composite of all-cause death, MI, stroke and any repeat revascularisation) at 5 years and its components, which were adjudicated by an independent clinical events committee.

Statistical analysis
All analyses were performed on the intention-to-treat population. Continuous variables are expressed as median and IQR and compared using the Kruskal-Wallis H test. Categorical variables are presented as counts and percentages and compared using the χ² test or Fisher’s exact test as appropriate. The Kaplan-Meier method was used as the primary analysis to estimate the cumulative rates of events over time, and the log-rank test was performed to examine the differences between groups, with CIs for 95% ratios of the probability of events at 5 or 10 years.

As a supplementary analysis, the hazards of clinical endpoints were compared between the P-LAD and the non-P-LAD group using unadjusted and adjusted Cox proportional hazards models to calculate the HR and 95% CI. The covariates in the adjusted models were baseline variables of age, sex, body mass index, medically treated diabetes, hypertension, dyslipidaemia, current smokers, previous MI, previous cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, prescription of statin at discharge, any bifurcations and anatomical SYNTAX score, which had been selected based on prior knowledge of the association of these variables with all-cause mortality and MACCE. The HRs between PCI and CABG were also assessed in the unadjusted Cox proportional hazards models stratified by P-LAD and non-P-LAD groups, with evaluation of the treatment-by-subgroup interaction.

In addition, the predicted 10-year all-cause mortality for PCI and CABG was also calculated using the SYNTAX Score II 2020, with assessment of calibration plots in each P-LAD subgroup and comparisons of the treatment benefit.

Statistical significance was defined as a two-sided p≤0.05. All analyses were performed using SPSS Statistics V.26 (IBM Corp., Armonk, 281 N.Y., USA) and R V.3.5.1 software (R Foundation for Statistical Computing, Vienna, Austria).

Patient and public involvement
No patients were involved in the design, conduct, reporting or dissemination plans of the present study.

RESULTS
Baseline characteristics
Out of the 1800 patients enrolled in the SYNTAX trial, 705 with LMCAD were excluded from the current analysis. Among the remaining 1095 patients with 3VD, 1088 (99.4%) were included in the present study, with 7 patients excluded due to missing information on P-LAD lesion. Out of the 1088 patients, 559 (51.4%) had at least one P-LAD lesion and were classified in the P-LAD group (figure 1).

The baseline characteristics of the patients according to presence or absence of a P-LAD lesion are summarised in table 1. Compared with those without a P-LAD lesion, the P-LAD group had a lower prevalence of previous MI, higher anatomical SYNTAX score and more frequent bifurcation lesions. There were no significant between-group differences in other characteristics, including age, proportion of women and average predicted rate of mortality by the SYNTAX Score II 2020 (table 1).

The baseline characteristics stratified according to the randomised revascularisation strategy in the P-LAD and the non-P-LAD group are presented in online supplemental table 1 and are generally well balanced.
Clinical outcomes between the P-LAD and the non-P-LAD group

The presence or absence of a lesion in P-LAD did not impact significantly on the unadjusted or adjusted risk of any clinical endpoints including MACCE at 5 years (unadjusted HR: 0.95, 95% CI 0.77 to 1.19, p = 0.674; adjusted HR: 0.89, 95% CI 0.70 to 1.14, p = 0.351) and its components and all-cause death at 10 years (unadjusted HR: 1.02, 95% CI 0.80 to 1.30, p = 0.863; adjusted HR: 0.95, 95% CI 0.72 to 1.26, p = 0.718; table 2).

Clinical outcomes of PCI versus CABG in the P-LAD and the non-P-LAD group

At 5 years, the rate of MACCE was significantly higher with PCI than CABG in both the P-LAD group (41.9% vs 25.7%; unadjusted HR: 1.54, 95% CI 1.29 to 1.83; unadjusted p value for interaction = 0.001) and the non-P-LAD group (40.7% vs 28.0%; unadjusted HR: 1.54, 95% CI 1.26 to 1.86, p < 0.001) and the non-P-LAD group (40.7% vs 28.0%; unadjusted HR: 1.54, 95% CI 1.26 to 1.86, p < 0.001) and the non-P-LAD group (40.7% vs 28.0%; unadjusted HR: 1.54, 95% CI 1.26 to 1.86, p < 0.001). No other treatment-by-subgroup interactions were seen for any of the other components of MACCE.

In the P-LAD group, the primary endpoint of all-cause death at 10 years was numerically higher with PCI than with CABG (28.8% vs 20.2%; HR: 1.47, 95% CI 1.03 to 2.09, p = 0.034); however, there was no evidence of a treatment-by-subgroup interaction (p value for interaction = 0.837; figure 2B and table 3).

Assessment of the SYNTAX Score II 2020 and treatment benefit in patients with or without P-LAD lesion

For exploratory purposes, we also investigated the clinical outcomes among patients with 3VD stratified according to the presence of P-LAD lesions and the SYNTAX Score II 2020.
Online supplemental figure 1 shows the calibration plots of the SYNTAX Score II 2020 for 10-year mortality in the P-LAD and non-P-LAD groups, and confirms the score’s acceptable discrimination and calibration, irrespective of the presence or absence of a P-LAD lesion.

Online supplemental figure 2 shows the absolute risk differences between CABG and PCI in each quarter for patients with and without a P-LAD lesion, respectively. In the P-LAD group, the (red) curve for absolute risk difference in mortality (treatment benefit of CABG over PCI) was helpfully calibrated, whereas in the non-P-LAD group the (blue) curve lacked precision.

When stratifying patients according to the treatment benefit predicted by the SYNTAX Score II 2020, PCI was predicted to be superior or equivalent to CABG in the first three quartiles, whereas CABG was superior to PCI in terms of lowering 10-year mortality in only the fourth quartile, irrespective of the presence or absence of a P-LAD lesion (online supplemental figures 3–5).

**DISCUSSION**

**P-LAD lesion and long-term clinical events in patients with 3VD and/or LMCA**

Compared with isolated lesions in other epicardial vessels, a focal lesion in P-LAD is considered high risk for adverse events and derives a mortality benefit from revascularisation. The anatomical SYNTAX score gives a P-LAD lesion the second highest score following a lesion in the LMCAD. In fact, in the present study, the P-LAD group had a significantly higher mean anatomical SYNTAX score compared with the non-P-LAD group (table 1). However, in the context of an average treatment effect, the risk of MACCE at 5 years or all-cause death at 10 years did not differ significantly between the presence or absence of a P-LAD lesion. Hence, in the context of 3VD, the presence or absence of a P-LAD lesion does not significantly increase adverse events, including MI and restenosis, as was also predicted by the SYNTAX Score II 2020 (table 1).

**Impact of P-LAD lesion on the treatment effects of CABG over PCI**

LIMA is the preferred conduit for grafting the LAD during a CABG operation, given its proven very long-term patency. Therefore, an isolated P-LAD lesion would be an ideal target for surgery, as supported by its class I recommendation in the ESC guidelines. However, in the current study, the survival benefit of CABG over PCI was only observed in patients without involvement of the P-LAD, with no statistically significant benefit observed in patients with a P-LAD lesion, even despite their significantly higher SYNTAX score compared with the non-P-LAD group.

In the PCI arm the risk of mortality or MACCE did not differ significantly irrespective of the involvement of a P-LAD, which is in line with recent reports, and presumably due to the fact that lesion characteristics such as large reference vessel diameter, minimal tortuosity and higher blood flow are all favourable for PCI. Only for MI there was a statistically significant treatment-by-subgroup interaction between revascularisation strategies and a P-LAD lesion (p=0.038). This finding might indicate that the beneficial effect of CABG in preventing MI is greater when the myocardial area subtended by the bypass graft is larger (ie, the lesion is located more proximally than in mid or distal). Nevertheless, no long-term survival benefit was observed with CABG over PCI in the P-LAD compared with the non-P-LAD group. Therefore, this finding may be a play of chance due to the limited number of MIs (35 in the P-LAD group and 37 in the non-P-LAD group) occurring during follow-up. Although further investigations will be needed to clarify whether CABG has a true beneficial effect over PCI for a P-LAD lesion, our findings suggest that when selecting a revascularisation strategy in cases of 3VD, a P-LAD lesion does not need any special consideration other than that already accounted for in the anatomical SYNTAX score.

---

**Table 1** Continued

|          | Proximal LAD n=559 | Non-proximal LAD n=529 | P value |
|----------|--------------------|-------------------------|---------|
| Aspirin  | 91.3 (501/549)     | 91.1 (471/517)          | 1.000   |
| Thienopyridine | 56.8 (312/549)     | 61.5 (318/517)          | 0.135   |
| Statin   | 78.9 (433/549)     | 81.2 (420/517)          | 0.358   |
| Beta blocker | 80.7 (443/549)     | 79.3 (410/517)          | 0.592   |
| ACEI     | 50.1 (275/549)     | 53.8 (278/517)          | 0.244   |
| ARB      | 9.3 (51/549)       | 8.7 (45/517)            | 0.749   |

Data are presented as median (IQR) or percentage (n).

P values highlighted in bold suggest statistical significance (p<0.05).

ACEI, ACE inhibitors; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; LAD, left anterior descending artery; LMCAD, left main coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; 2VD, two-vessel disease; 3VD, three-vessel disease.

---

**Table 2** Unadjusted and adjusted hazard risks for long-term clinical outcomes between patients with and without proximal LAD lesion

| Endpoints                          | Unadjusted | Adjusted |
|-----------------------------------|------------|----------|
|                                   | n          | HR (95% CI) | P value | HR (95% CI) | P value |
| All-cause death at 10years        | 263/1088   | 1.02 (0.80 to 1.30) | 0.863   | 0.95 (0.72 to 1.26) | 0.718   |
| All-cause death at maximum follow-up | 330/1088 | 1.83 (0.83 to 1.28) | 0.786   | 0.98 (0.77 to 1.26) | 0.886   |
| MACCE at 5years                   | 323/1088   | 0.95 (0.77 to 1.19) | 0.674   | 0.89 (0.70 to 1.14) | 0.351   |
| All-cause death at 5years         | 124/1088   | 0.96 (0.68 to 1.37) | 0.840   | 0.87 (0.58 to 1.31) | 0.512   |
| Cardiac death at 5years           | 68/1088    | 0.88 (0.55 to 1.42) | 0.601   | 0.89 (0.51 to 1.56) | 0.682   |
| MI at 5years                      | 72/1088    | 0.88 (0.55 to 1.39) | 0.583   | 0.83 (0.50 to 1.38) | 0.471   |
| Stroke at 5years                  | 32/1088    | 1.22 (0.60 to 2.44) | 0.584   | 1.15 (0.54 to 2.46) | 0.710   |
| Revascularisation at 5years       | 190/1088   | 0.88 (0.66 to 1.17) | 0.386   | 0.82 (0.60 to 1.12) | 0.207   |

The covariates in the adjusted models included age, sex, body mass index, medically treated diabetes, hypertension, dyslipidaemia, current smokers, previous myocardial infarction, previous cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, prescription of statin at discharge, any bifurcations and anatomical SYNTAX score.

‘n’ refers to the number of patients having events/total number of patients in the model.

LAD, left anterior descending artery; MACCE, major adverse cardiac or cerebrovascular events; MI, myocardial infarction; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery.
Coronary artery disease

Of note, the prescription rates of postprocedural medical therapies were significantly lower following CABG compared with PCI in both the P-LAD and non-P-LAD groups (table 1), which may partially negate the potential benefit of CABG.24

Recently, there is growing interest in hybrid coronary revascularisation procedures combining LIMA graft to the LAD with PCI for lesions in other epicardial vessels.25 Given the limited patency of saphenous vein grafts,26 this hybrid revascularisation strategy may be an important treatment option especially in patients with MVD, including a P-LAD lesion. Although this is beyond the scope of the current study, further studies are warranted to address this.

Average treatment effect versus personalised treatment benefit in patients with or without P-LAD

A dichotomic selection by a practitioner of privileged therapy between two treatment options mostly relies on the outcome of an average treatment effect, traditionally provided by an absolute difference of risk or benefit derived from Kaplan-Meier estimates in randomised trials. However, it is always appealing to identify a single major prognostic factor which more specifically predicts MACCE or mortality. Classically, a multivariable analysis will identify a variety of risk factors and their potential positive or negative interaction with one or the other alternative treatment.

From the patient’s perspective, however, it remains of paramount importance to have a personalised assessment of risk and benefit by combining multiple independent determinants of outcome while integrating their mutual interactions.16 The goal is to identify in an heterogeneous population who is going to benefit from the novel treatment, who is going to have an equivocal outcome and who is going to be harmed by this new therapy.

The methodological foundation of this approach lies in the accuracy of the predicted outcomes from each modality of treatment, allowing personalised and individual predictions of the treatment benefit of one treatment versus the other.16 18 Given the fact that the SYNTAX Score II 2020 had similar impact on predicting mortality in both the P-LAD and non-P-LAD groups, a P-LAD lesion may not need to be taken into account when using the SYNTAX score II 2020 in patients with 3VD.

Limitations

Our study has several limitations. First, the current subanalysis of the SYNTAXES trial was not prespecified and the patients were not randomised or stratified according to the presence or absence of a P-LAD lesion. Therefore, all the results were non-confirmatory and should be regarded as hypothesis-generating only. Second, patients with extremely complex CAD who were deemed not to be able to undergo PCI were excluded in the randomised cohort and were entered in the nested CABG registry.27 Hence, our results might not be applicable to those with very complex P-LAD lesions. Third, the SYNTAX trial was conducted between 2005 and 2007 with an unrestricted use of first-generation paclitaxel drug-eluting stents for treatment with PCI. The technological improvements of PCI devices as well as medical treatment strategies may limit the generalisability of our findings to current practice. It is, however, unavoidable that the findings from long-term follow-up data are based on outdated technology while the evidence for contemporary technology can be derived only from short-term follow-up studies. Fourth, the SYNTAX Score II 2020 was developed from the SYNTAX(ES) study population, which is the same as the current study and the original landmark SYNTAX trial. Hence, the current findings derived from the SYNTAX Score II 2020 may be overestimated and the predictive ability of the score when applied to real-world populations may be inferior to what was observed in the current study. However, the SYNTAX Score II 2020 has been externally validated in four randomised trials (the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL), the Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary

Figure 2 Cumulative incidence of (A) MACCE up to 5 years and (B) all-cause death up to 10 years after PCI or CABG in patients with or without P-LAD stenosis. (A) The incidence of MACCE at 5 years was significantly higher in PCI than in CABG irrespective of the involvement of a P-LAD lesion. (B) In the P-LAD group, all-cause death at 10 years did not differ significantly between PCI and CABG, whereas in the non-P-LAD group PCI was associated with a significantly higher risk of all-cause death at 10 years compared with CABG, although there was no significant treatment-by-subgroup interaction. CABG, coronary artery bypass grafting; MACCE, major adverse cardiac or cerebrovascular events; PCI, percutaneous coronary intervention; P-LAD, proximal left anterior descending artery.
Artery Disease (PRECOMBAT), the Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease (BEST), the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) and in a large, contemporary registry and showed a predictive performance as good as in the original SYNTAX cohort. Finally, the extended follow-up of the SYNTAXES trial up to 10 years was only for survival status, with data for other clinical endpoints with independent adjudication limited to 5 years.

CONCLUSIONS
Among patients with 3VD, the presence of a P-LAD lesion was not associated with a higher incidence of MACCE at 5 years or all-cause death at 10 years and there was also no evidence that the presence of a P-LAD impacted on the treatment effects of PCI and CABG. The SYNTAX Score II 2020 identified individuals who benefited from differential long-term survival after CABG or PCI in patients with 3VD and a P-LAD lesion.

Author affiliations
1. Department of Cardiology, University of Amsterdam, Amsterdam, The Netherlands
2. Department of Cardiology, National University of Ireland Galway, Galway, Ireland
3. Department of Cardiology, Radboud University Nijmegen, Nijmegen, The Netherlands
4. Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands
5. Department of Cardiothoracic Surgery, Baylor University Medical Center at Dallas, Dallas, Texas, USA
6. Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
7. Interventional Cardiology, Ramsay Générale de Santé, Paris, France
8. Department of Cardiothoracic Surgery, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands
9. Department of Cardiology, University Hospital of Leipzig Heart Center University Hospital, Leipzig, Germany
10. Department of Surgery, University of Toronto, Toronto, Ontario, Canada
11. Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Ontario, Canada
12. Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK

Acknowledgements
Dr. Serruys had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Collaborators
SYNTAX Extended Survival Principal Investigators: dr. Stuart J. Head, MD PhD, Erasmus MC, Rotterdam, The Netherlands SYNTAX Extended Survival Principal Investigator/Study director: Daniel J.F.M. Thuijs, MD, Erasmus MC, Rotterdam, The Netherlands SYNTAX Extended Survival Participating sites with Local Chief Investigators: 1. Aalst, Onze Lieve Vrouwen Ziekenhuis (OLVZ), Belgium: Filipp Casmann, Bernard de Bryne, MD 2. Aarhus, Aarhus University Hospital, Denmark: Evald Hej Christiansen, MD PhD 3. Alicante, Hospital General de Alicante, Spain: Juan M. Ruiz-Nodar, MD PhD 4. Antwerp, ZNA Middelheim, Belgium: Paul Veermeersch, MD 5. Bad Oeynhausen, Universitätsklinikum der Ruhr-Universität Bochum, Germany: Werner Schultz, MD 6. Barcelona, Hospital Clinic de Barcelona, Spain: Manel Sabaté, MD PhD 7. Bergamo, Ospedale Papa Giovanni di Bergamo, Italy; Giuliol Guaglium, MD 8. Berlin, Charité – Universitätsmedizin Berlin, Germany: Herko Grubitzsch, MD PhD 9. Berlin, Charité – Universitätsmedizin Berlin, Germany: Karl Stangl, MD 10. Bordeaux, Clinique ST Augustin, France: Olivier Darremde, MD 11. Breda, Aphia Ziekenhuis, The Netherlands: M. Bentala, MD PhD 12. Dallas, Baylor University Medical Centre, TX, USA: Robert Stoler, MD 13. Dallas, Medical City Dallas Hospital, TX, USA: Michael J. Mack, MD 14. Debrecen, University of Debrecen, Hungary: Tamás Szerain, MD PhD 15. Denver, UCH Denver Colorado, USA: John K. Bucline, MD, and Myles S. Guber, MD 16. Dhenscheva, Catharina Ziekenhuis, The Netherlands: Niels Verberkmoes, MD, Ferdi Akca, MD PhD 17. Eavonston, Northshore University HealthSystem, IL, USA: Ted Feldman, MD 18. Freiburg, Heart Center, University of Freiburg, Germany: Friedhelm Beyerdsorf, MD PhD 19. Gent, Universitair Ziekenhuis Gent, Belgium: Benny Drigehe, MD 20. Glasgow, Golden Jubilee National Hospital, Clydebank, UK: Keith Oldroyd, MD, Geoff Berg, MD 21. Gothenburg, Sahlgrenska University Hospital, Sweden: Anders Jeppsson, MD PhD 22. Grand Blanc, Genesys Regional Medical Center, Grand Blanc, MI, USA: Kimberly Barber, MD PhD 23. Grand Rapids, Spectrum Health Hospitals Cook Research Department, MI, USA; Kevin Wolschleger, MD, John Heiser, MD 24. Groningen, Universitair Medisch Centrum Groningen, The Netherlands: Pim van der Harst, MD PhD, Massimo A. Mariani, MD PhD 25. Hamburg, University Heart Center Hamburg, Germany: Hermann Reichenhauer, MD PhD 26. Helsinki, University of Helsinki Meilahti Hospital, Finland: Christoffer Stark, MD, Mika Laine, MD PhD 27. Honolulu, Kaiser Permanente, HI, USA: Paul C. Ho, MD and John C. Chen, MD 28. Hyannis, Cape Cod Hospital, MA, USA: Richard Zelman, MD 29. Iowa, University of Iowa Hospitals & Clinics, IA, USA: Phillip A. Horwitz, MD 30. Katowice, Centreum Badaczko-Rozwazowa, Polish Heart Center of Poland, Poland: Agata Krauze, MD PhD 31. Kiel, Universitätsklinikum Kiel, Germany: Christina Grothues, MD 32. Krakow, John Paul II Hospital, Poland: Dariusz Dudek, MD PhD 33. Langhorne, St. Mary Medical Center, PA, USA: George Heyrich, MD 34. Leipzig, Heart Center, University of Leipzig, Germany: Pirzoe Davirawala, MD, Thilo Noack, MD 35. Liege, University Hospital of Liege, Belgium: Victor LeGrand, MD PhD 36. Lübeck, University Medicine Lübeck, Germany: Stefan Ensminger, MD, Boris Nassier, MD 37. Madrid, Hospital Clinico San Carlos, Spain: Javier Escaned, MD PhD, Reddy Guera, MD 40. Massa, Fondazione CNR-Regione Toscana for the Ricerca Medica e di
Coronary artery disease

Sanità Pubblica-Ospedale del Cuore G.Pasquiniucci, Italy: Sergio Berti, MD 41. Massy, Cardiovascular Institute Paris-Sud (ICPS), Hopital privé Jacques Cartier, Ramsgay, Générale de Santé Massy, France : Marie-Claude Morice, MD 42. Milan, San Raffaele Hospital, Milan, Italy: Alide Chieffe, MD 43. Minneapolis, Minneapolis Cardiovascular Foundation Institute, MN, USA: Nicholas Burke, MD, Michael Mooney, MD 44. Mirano, Ospedale di Mirano, Italy: Alvise Spolaor, MD 45. Munich, Klinikum der Universität München, Campus Großhadern, Germany; Christian Hagl, MD, Michael Nábauer, MD 46. Nieuwegein, Sint-Antoniën Ziekenhuis, The Netherlands: Maarten Jan Suttorp, MD PhD 47. Norfolk, Sentara Cardiovascular Research Institute, Norfolk, VA, USA: Ronald A. Stine, MD 48. Oklahoma, Oklahoma Cardiovascular Research Group, OK, USA: Thomas McGarry, MD PhD, Scott Lucas, MD 49. Oslo, Oslo universitetssykehus HF, Norway: Knut Endresen, MD PhD 50. Orlando, Florida Hospital Cardiovascular Research, Florida, USA: Andrew Tausigg, MD, Kevin Accola, MD 51. Pavia, IRCCS Policlinico San Matteo, Italy: Umberto Canosi, BS 52. Pecs, University Hospital of Pecs, Hungary: Ivan Horvath, MD PhD 53. Petoskey, Cardiac & Vascular Research Center of Northern Michigan, Michigan, USA; Louis Cannon, MD, John D. Talbott, MD, Chris W. Atkins, MD 54. Portland, Maine Medical Center, ME, USA: Robert Kramer, MD 55. Prague, Interni Klinika VFN, Czech Republic: Michael Aschermann, MD 56. Raleigh, WakeMed Health & Hospitals, Raleigh, NC, USA; William Killinger, MD 57. Riga, Latvian Centre of Cardiology, Latvia: Inga Narbute, MD 58. Rochester, Mayo Clinic, MN, USA: David R. Holmes Jr., MD 59. Rome, Catholic University of the Sacred Heart, Italy: Francesco Burzotta, MD 60. Rotterdam, Erasmus University Medical Centre, The Netherlands: Ad J.J.C. Bogers, MD, Felix Zijlstra, MD PhD 61. Rouen, Centre Hôpital Universitaire Rouen, Hôpital Charles Nicolle, France: Helene Eltschchnoff, MD 62. Rouen, Centre Saint-Hilaire Rouen, France: Jacques Berland, MD 63. Rozzano, Instituto Clinico Humanitas, Italy: Giulio Stefanini, MD PhD 64. Salamanca, Hospital Clinico Salamanca, Spain: Ignacio Cruz Gonzalez, MD 65. Salzburg, Dept. of Cardiology, Paracelsus Medical University Salzburg, Austria: Uta Hoppe, MD 66. San Antonio, San Antonio Endovascular and Heart Inst., TX, USA: Radoslav Stefan Kiese, MD, Bartlomiej Gora, MD 67. Stockholm, Karolinska University Hospital, Sweden: Anders Ahlsson, MD PhD, Matthias Corbascio, MD PhD 68. Stonybrook, Stony Brook University, NY, USA: Thomas V. Billinger, MD 69. Toulouse, Centre Hôpital Universitaire Rangueil, France: Daniel Fournier, MD 70. Trenton, New Commons Attribution Non-commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**ORCID iDs**
Masafumi Ono http://orcid.org/0000-0002-3919-5648
Rutao Wang http://orcid.org/0000-0002-1473-9709
Scott Garg http://orcid.org/0000-0002-8911-0278
Patrick W Sensuys http://orcid.org/0000-0002-9636-1104

**Supplemental material**
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non-commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Provenance and peer review**
Not commissioned; externally peer reviewed.

**Data availability statement**
Data are available upon reasonable request.

**Acknowledgements**
Anonymised data that support the findings of this study are available from the corresponding author on reasonable request.

**Funding**
and controlled the decision to publish.

**Ethics approval**
This study involves human participants and the protocol was approved by the institutional review board of all 85 sites. The SYNTAX and SYNTAXES trials were approved by the ethics committees at each investigating centre. Follow-up was performed in accordance with local law and regulations of each participating institution and complied with the Declaration of Helsinki and Good Clinical Practice. Participants gave informed consent to participate in the study before taking part.

**Competing interests**
PWS reports personal fees from Biosensors, Micel Technologies, Sino Medical Sciences Technology, Philips/Volcano, Xeltis and HeartFlow, outside the submitted work. HH reports a grant for studying overseas from the Japanese Circulation Society and a grant from Fukuda Foundation for Medical Technology, outside the submitted work. JIP reports personal fees and non-financial support from Philips/Volcano, outside the submitted work. M-CM is CEO and shareholder of CERC, a CRO not involved in this trial, and is a minor shareholder of Electroducer. SH reports to work as employee of Medtronic, outside the submitted work. APK reports to work as employee of Medtronic, outside the submitted work. All other authors have no conflict of interest to declare.

**Patient and public involvement**
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**
Not required.

**Extended Survival, yet did contribute to the SYNTAX trial) 85. Sacramento, 2 Klein LW, Weintraub WS, Agarwal JB, 1994;344:563–70.

**References**
Leaman DM, Brower RW, Meester GT, et al. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981;63:285–99.
Klein LW, Weintraub WS, Agarwal JB, et al. Prognostic significance of severe narrowing of the proximal portion of the left anterior descending coronary artery. Am J Cardiol 1986;58:42–6.
Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass graft surgery Trialists collaboration. Lancet 1994;344:563–70.
Sianos G, Morel M-A, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219–27.
Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
Matsoukis IL, Karanasos A, Patsa C, et al. Long-term clinical outcomes of coronary artery bypass graft surgery compared to those of percutaneous coronary intervention with second generation drug eluting stents in patients with stable angina and an isolated lesion in the proximal left anterior descending artery. Catheter Cardiovasc Interv 2021;98:447–57.
Hannan ES, Zhong Y, Cozzens K, et al. Revascularization for isolated proximal left anterior descending artery disease. Ann Thorac Surg 2021;112:555–62.
Li S, Zhang H, Xiao C, et al. Robotically assisted coronary artery bypass graft surgery versus drug-eluting stents for patients with stable isolated proximal left anterior descending disease. J Card Surg 2021;36:1864–71.
Garg S, Sarno G, Gutiérrez-Chico JL, et al. Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study. EuroIntervention 2011;6:1060–7.

**Disclosure**
The study funders had no role in the study design, data collection, data analyses and interpretation of the study data, nor were involved in the decision to publish the final manuscript. The principal investigators and authors had complete scientific freedom.

**Authors’ note**
This article is an update of an article published in Heart in 1999.

**Correction notice**
This is an updated version of an article published in Heart in 1999.
Coronary artery disease

10 Cavalcante R, Sotomi Y, Zeng Y, et al. Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. Heart 2017;103:428–33.

11 Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961–72.

12 Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019;394:1325–34.

13 Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629–38.

14 Ono M, Serruys PW, Hara H, et al. 10-Year follow-up after revascularization in elderly patients with complex coronary artery disease. J Am Coll Cardiol 2021;77:2761–73.

15 Austen WG, Edwards JE, Fye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the AD hoc Committee for grading of coronary artery disease, Council on cardiovascular surgery, American heart association. Circulation 1975;51:5–40.

16 Serruys PW, Chichareon P, Modolo R, et al. The SYNTAX score on its way out or ... towards artificial intelligence: Part I. EuroIntervention 2020;16:44–59.

17 Pocock SJ, McMurray JJV, Collier TJ. Statistical controversies in reporting of clinical trials: Part 2 of a 4-Part series on statistics for clinical trials. J Am Coll Cardiol 2015;66:2648–62.

18 Takahashi K, Serruys PW, Fuster V, et al. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet 2020;396:1399–412.

19 Thiele H, Neumann-Schröedl P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009;53:2324–31.

20 Hannan EL, Zhong Y, Walford G, et al. Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 2014;64:2717–26.

21 Kjøller-Hansen L, Bilgaard N, Kelbaek H, et al. Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments. EuroIntervention 2018;14:764–71.

22 Takahashi K, Wang R, Kawashima H, et al. Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: insights from the global leaders trial. Int J Cardiol 2020;320:27–34.

23 Codner P, Saada M, Sakho Q, et al. Proximal left anterior descending artery treatment using a bioresorbable polymer coating sirolimus-eluting stent: real-world outcomes from the multicenter prospective e-Ulimest registry. J Am Heart Assoc 2019;8:e013786.

24 Kawashima H, Serruys PW, Ono M, et al. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. J Am Coll Cardiol 2021;78:27–38.

25 Torregrossa G, Sá MP, Van den Eynde J, et al. Hybrid robotic off-pump versus conventional on-pump and off-pump coronary artery bypass graft surgery in women. J Card Surg 2022;37:895–905.

26 Davienwala PM, Gao C, Thuijs D. Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. Eur Heart J 2021.

27 Head SJ, Holmes DR, Mack MJ, et al. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC Cardiovasc Interv 2012;5:618–25.

28 Takahashi K, van Klaveren D, Steyerberg EW, et al. Concerns with the new SYNTAX score - Authors’ reply. Lancet 2021;397:795–6.

29 Hara H, Shomi H, van Klaveren D, et al. External Validation of the SYNTAX Score II 2020. J Am Coll Cardiol 2021;78:1227–38.